<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04884178</url>
  </required_header>
  <id_info>
    <org_study_id>CPRO-000001</org_study_id>
    <nct_id>NCT04884178</nct_id>
  </id_info>
  <brief_title>PMCF Study of Preloaded Trifocal IOL</brief_title>
  <official_title>Post-Market Clinical Follow-up Study of Preloaded Trifocal IOL Delivery System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ICARES Medicus, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AST Products, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ICARES Medicus, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate the safety, effectiveness and patient satisfaction of the&#xD;
      Trifocal Intraocular Lens after implanted to replace the natural lens following cataract&#xD;
      removal.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a single-arm unmasked clinical evaluation study of safety, effectiveness and&#xD;
      patient satisfactions of the Trifocal Intraocular Lens after successful bilateral cataract&#xD;
      surgery. Subjects will be assessed pre-operative, operative date and at 1-2 days, 1-2 weeks,&#xD;
      1-2 months, 3-4 months and 6 months post-operative. Clinical evaluations will include&#xD;
      probability of adverse events, patient satisfaction questionnaire, as well as measurements of&#xD;
      monocular and bilateral far, intermediate and near visual acuity as a result of Trifocal Lens&#xD;
      performance, etc.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 23, 2021</start_date>
  <completion_date type="Anticipated">March 24, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 24, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Photopic monocular CDVA, 400 cm</measure>
    <time_frame>6 Months post second eye implantation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Photopic monocular CIVA, 60 cm</measure>
    <time_frame>6 Months post second eye implantation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Photopic monocular CNVA, 40 cm</measure>
    <time_frame>6 Months post second eye implantation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rates of adverse events vs. ISO 11979-7:2018 SPE rate</measure>
    <time_frame>6 Months post second eye implantation</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Trifocal Preloaded IOL Delivery System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bilateral trifocal IOLs implanted through preloaded IOL Delivery System in the capsular bag in the posterior chamber of the eye during cataract surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Trifocal Preloaded IOL Delivery System</intervention_name>
    <description>UV and blue-light filtering foldable trifocal IOL with a +2.2 diopter (D) addition power of intermediate visual acuity and a +3.3 D addition power of near visual acuity. This device is approved in Taiwan.</description>
    <arm_group_label>Trifocal Preloaded IOL Delivery System</arm_group_label>
    <other_name>Asqelio Trifocal</other_name>
    <other_name>TFPIO130Y</other_name>
    <other_name>TFLIO130</other_name>
    <other_name>aspicio Trifocal</other_name>
    <other_name>PTF60Y</other_name>
    <other_name>TF60</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Bilateral cataracts: Adults, 20 years of age or older at the time of informed consent,&#xD;
             of either gender, diagnosed with bilateral cataracts&#xD;
&#xD;
          -  Desire for high post-operative spectacle independence&#xD;
&#xD;
          -  Willingness to cooperate with and complete all post-operative visits&#xD;
&#xD;
          -  Calculated lens power within +5.0 D and +34.0 D&#xD;
&#xD;
          -  Planned cataract removal by phacoemulsification&#xD;
&#xD;
          -  Clear intraocular media other that cataracts in both eyes&#xD;
&#xD;
          -  Potential post-operative visual acuity of 20/25 or better&#xD;
&#xD;
          -  Ability to comprehend and sign an informed consent&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  More than 1.0 D of pre-operative corneal astigmatism&#xD;
&#xD;
          -  Expected post-operative astigmatism of more than 0.75 D&#xD;
&#xD;
          -  Mature/dense cataract which makes the pre-operative fundus examination difficult&#xD;
&#xD;
          -  Previous ocular surgery or trauma&#xD;
&#xD;
          -  Clinically significant irregular astigmatism&#xD;
&#xD;
          -  Choroidal hemorrhage&#xD;
&#xD;
          -  Microphthalmos&#xD;
&#xD;
          -  Severe corneal dystrophy&#xD;
&#xD;
          -  Medically controlled or uncontrolled glaucoma&#xD;
&#xD;
          -  Clinically significant macular/RPE changes&#xD;
&#xD;
          -  Concomitant severe eye disease&#xD;
&#xD;
          -  Severe optic nerve atrophy&#xD;
&#xD;
          -  Diabetic retinopathy, proliferative or macular edema&#xD;
&#xD;
          -  Amblyopia&#xD;
&#xD;
          -  Extremely shallow anterior chamber&#xD;
&#xD;
          -  Chronic sever uveitis&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  Previous retinal detachment&#xD;
&#xD;
          -  Previous corneal transplant&#xD;
&#xD;
          -  Concurrent participation in another drug or device investigation&#xD;
&#xD;
          -  May be expected to require other ocular surgery during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chiun-Ho Hou, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ICARES Medicus, Inc.</last_name>
    <phone>+886-3-657-9530</phone>
    <email>info@ICARESmedicus.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital, Linkou</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Po-Hsuen Chen</last_name>
    </contact>
    <investigator>
      <last_name>Chiun-Ho Hou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juahn-Shing Lee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 7, 2021</study_first_submitted>
  <study_first_submitted_qc>May 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2021</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cataract</keyword>
  <keyword>Trifocal</keyword>
  <keyword>IOL</keyword>
  <keyword>Intraocular lens</keyword>
  <keyword>Preloaded</keyword>
  <keyword>Aphakic</keyword>
  <keyword>Spectacle independence</keyword>
  <keyword>Asqelio</keyword>
  <keyword>aspicio</keyword>
  <keyword>AST Products</keyword>
  <keyword>ICARES</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

